Wnt Signaling in Renal Cell Carcinoma

Wnt Signaling in Renal Cell Carcinoma

Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2016-06, Vol.8 (6), p.57
Hauptverfasser: Xu, Qi, Krause, Mirja, Samoylenko, Anatoly, Vainio, Seppo
Format: Artikel
Sprache:eng
Schlagworte:
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page 57
container_title Cancers
container_volume 8
creator Xu, Qi
Krause, Mirja
Samoylenko, Anatoly
Vainio, Seppo
description Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/β-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/β-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers.
doi_str_mv 10.3390/cancers8060057
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4931622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1798994384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-a426fccdb080c61fb07356ea2f46f2c4a106e56f9f82bcf2797db746728d38a53</originalsourceid><addsrcrecordid>eNpVUEtLAzEQDqLYUnv1KHsRvGzNa_O4CFJ8QUHwgceQzSY1sputyVbw3xuplnYOMx_MN9_MfACcIjgjRMJLo4OxMQnIIKz4ARhjyHHJmKSHO3gEpil9wByEIM74MRhhTjAmuBqD87cwFM9-GXTrw7LwoXiyGRdz2-ako_Gh7_QJOHK6TXb6Vyfg9fbmZX5fLh7vHubXi9LQig2lppg5Y5oaCmgYcjXkpGJWY0eZw4ZqBJmtmJNO4No4zCVvak4Zx6IhQldkAq42uqt13dnG2DBE3apV9J2O36rXXu13gn9Xy_5LUUkQyy9NwMWfQOw_1zYNqvPJ5F90sP06KcSlkJISQTN1tqGa2KcUrduuQVD92qv27c0DZ7vHben_ZpIfch12Xw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1798994384</pqid></control><display><type>article</type><title>Wnt Signaling in Renal Cell Carcinoma</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Xu, Qi ; Krause, Mirja ; Samoylenko, Anatoly ; Vainio, Seppo</creator><creatorcontrib>Xu, Qi ; Krause, Mirja ; Samoylenko, Anatoly ; Vainio, Seppo</creatorcontrib><description>Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/β-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/β-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers8060057</identifier><identifier>PMID: 27322325</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>Review</subject><ispartof>Cancers, 2016-06, Vol.8 (6), p.57</ispartof><rights>2016 by the authors; licensee MDPI, Basel, Switzerland. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-a426fccdb080c61fb07356ea2f46f2c4a106e56f9f82bcf2797db746728d38a53</citedby><cites>FETCH-LOGICAL-c456t-a426fccdb080c61fb07356ea2f46f2c4a106e56f9f82bcf2797db746728d38a53</cites><orcidid>0000-0001-9319-3566</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931622/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931622/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27322325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Qi</creatorcontrib><creatorcontrib>Krause, Mirja</creatorcontrib><creatorcontrib>Samoylenko, Anatoly</creatorcontrib><creatorcontrib>Vainio, Seppo</creatorcontrib><title>Wnt Signaling in Renal Cell Carcinoma</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/β-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/β-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers.</description><subject>Review</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVUEtLAzEQDqLYUnv1KHsRvGzNa_O4CFJ8QUHwgceQzSY1sputyVbw3xuplnYOMx_MN9_MfACcIjgjRMJLo4OxMQnIIKz4ARhjyHHJmKSHO3gEpil9wByEIM74MRhhTjAmuBqD87cwFM9-GXTrw7LwoXiyGRdz2-ako_Gh7_QJOHK6TXb6Vyfg9fbmZX5fLh7vHubXi9LQig2lppg5Y5oaCmgYcjXkpGJWY0eZw4ZqBJmtmJNO4No4zCVvak4Zx6IhQldkAq42uqt13dnG2DBE3apV9J2O36rXXu13gn9Xy_5LUUkQyy9NwMWfQOw_1zYNqvPJ5F90sP06KcSlkJISQTN1tqGa2KcUrduuQVD92qv27c0DZ7vHben_ZpIfch12Xw</recordid><startdate>20160617</startdate><enddate>20160617</enddate><creator>Xu, Qi</creator><creator>Krause, Mirja</creator><creator>Samoylenko, Anatoly</creator><creator>Vainio, Seppo</creator><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9319-3566</orcidid></search><sort><creationdate>20160617</creationdate><title>Wnt Signaling in Renal Cell Carcinoma</title><author>Xu, Qi ; Krause, Mirja ; Samoylenko, Anatoly ; Vainio, Seppo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-a426fccdb080c61fb07356ea2f46f2c4a106e56f9f82bcf2797db746728d38a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Qi</creatorcontrib><creatorcontrib>Krause, Mirja</creatorcontrib><creatorcontrib>Samoylenko, Anatoly</creatorcontrib><creatorcontrib>Vainio, Seppo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Qi</au><au>Krause, Mirja</au><au>Samoylenko, Anatoly</au><au>Vainio, Seppo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Wnt Signaling in Renal Cell Carcinoma</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2016-06-17</date><risdate>2016</risdate><volume>8</volume><issue>6</issue><spage>57</spage><pages>57-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/β-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/β-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>27322325</pmid><doi>10.3390/cancers8060057</doi><orcidid>https://orcid.org/0000-0001-9319-3566</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2016-06, Vol.8 (6), p.57
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4931622
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Review
title Wnt Signaling in Renal Cell Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T04%3A11%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Wnt%20Signaling%20in%20Renal%20Cell%20Carcinoma&rft.jtitle=Cancers&rft.au=Xu,%20Qi&rft.date=2016-06-17&rft.volume=8&rft.issue=6&rft.spage=57&rft.pages=57-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers8060057&rft_dat=%3Cproquest_pubme%3E1798994384%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1798994384&rft_id=info:pmid/27322325&rfr_iscdi=true